254 related articles for article (PubMed ID: 20580245)
1. Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: the impact of 2-(18)F-fluoro-2-deoxy-D-glucose positron emission tomogram mediastinal staging.
Barnett S; Baste JM; Murugappan K; Tog C; Berlangieri S; Scott A; Seevanayagam S; Knight S
Eur J Cardiothorac Surg; 2011 Jan; 39(1):96-101. PubMed ID: 20580245
[TBL] [Abstract][Full Text] [Related]
2. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
[TBL] [Abstract][Full Text] [Related]
3. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
Gómez-Caro A; Garcia S; Reguart N; Arguis P; Sanchez M; Gimferrer JM; Marrades R; Lomeña F
Eur J Cardiothorac Surg; 2010 May; 37(5):1168-74. PubMed ID: 20116273
[TBL] [Abstract][Full Text] [Related]
4. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
Gómez-Caro A; Boada M; Cabañas M; Sanchez M; Arguis P; Lomeña F; Ramirez J; Molins L
Eur J Cardiothorac Surg; 2012 Jul; 42(1):93-100; discussion 100. PubMed ID: 22290911
[TBL] [Abstract][Full Text] [Related]
5. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.
Al-Sarraf N; Aziz R; Gately K; Lucey J; Wilson L; McGovern E; Young V
Eur J Cardiothorac Surg; 2008 Jan; 33(1):104-9. PubMed ID: 17977738
[TBL] [Abstract][Full Text] [Related]
6. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
Raz DJ; Odisho AY; Franc BL; Jablons DM
J Thorac Cardiovasc Surg; 2006 Nov; 132(5):1189-95. PubMed ID: 17059942
[TBL] [Abstract][Full Text] [Related]
7. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
8. False-positivity of mediastinal lymph nodes has negative effect on survival in potentially resectable non-small cell lung cancer.
Iskender I; Kadioglu SZ; Cosgun T; Kapicibasi HO; Sagiroglu G; Kosar A; Kir A
Eur J Cardiothorac Surg; 2012 Apr; 41(4):874-9. PubMed ID: 22423060
[TBL] [Abstract][Full Text] [Related]
9. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
[TBL] [Abstract][Full Text] [Related]
10. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.
Ose N; Sawabata N; Minami M; Inoue M; Shintani Y; Kadota Y; Okumura M
Eur J Cardiothorac Surg; 2012 Jul; 42(1):89-92. PubMed ID: 22290887
[TBL] [Abstract][Full Text] [Related]
11. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
Trister AD; Pryma DA; Xanthopoulos E; Kucharczuk J; Sterman D; Rengan R
Am J Clin Oncol; 2014 Apr; 37(2):135-9. PubMed ID: 23111361
[TBL] [Abstract][Full Text] [Related]
13. Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer.
Perigaud C; Bridji B; Roussel JC; Sagan C; Mugniot A; Duveau D; Baron O; Despins P
Eur J Cardiothorac Surg; 2009 Oct; 36(4):731-6. PubMed ID: 19632852
[TBL] [Abstract][Full Text] [Related]
14. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
15. Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.
Harders SW; Madsen HH; Hjorthaug K; Arveschoug AK; Rasmussen TR; Meldgaard P; Hoejbjerg JA; Pilegaard HK; Hager H; Rehling M; Rasmussen F
Cancer Imaging; 2014 Jun; 14(1):23. PubMed ID: 25608616
[TBL] [Abstract][Full Text] [Related]
16. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.
Ripley RT; Suzuki K; Tan KS; Adusumilli PS; Huang J; Park BJ; Downey RJ; Rizk NP; Rusch VW; Bains M; Jones DR
J Thorac Cardiovasc Surg; 2016 Apr; 151(4):969-77, 979.e1-3. PubMed ID: 26614420
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
19. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
20. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]